Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · IEX Real-Time Price · USD
20.77
+0.89 (4.48%)
At close: Mar 27, 2024, 4:00 PM
20.35
-0.42 (-2.02%)
After-hours: Mar 27, 2024, 6:52 PM EDT
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 48.89, with a low estimate of 28 and a high estimate of 95. The average target predicts an increase of 135.39% from the current stock price of 20.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DNLI stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 2 | 3 | 3 | 4 | 4 |
Buy | 7 | 8 | 7 | 7 | 5 | 5 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 10 | 10 | 10 | 10 | 9 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $73 → $50 | Strong Buy | Maintains | $73 → $50 | +140.73% | Feb 29, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $105 → $95 | Strong Buy | Maintains | $105 → $95 | +357.39% | Feb 28, 2024 |
Wedbush | Wedbush | Buy Reiterates $31 | Buy | Reiterates | $31 | +49.25% | Feb 28, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $105 | Strong Buy | Reiterates | $105 | +405.54% | Feb 22, 2024 |
Citigroup | Citigroup | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +54.07% | Dec 13, 2023 |
Financial Forecast
Revenue This Year
76.15M
from 330.53M
Decreased by -76.96%
Revenue Next Year
162.84M
from 76.15M
Increased by 113.84%
EPS This Year
-2.77
from -1.06
EPS Next Year
-2.28
from -2.77
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 283.0M | 395.2M | 592.3M | 1.2B | 1.9B |
Avg | 76.2M | 162.8M | 226.7M | 423.8M | 683.6M |
Low | n/a | n/a | 12.2M | 9.2M | 176.4M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -14.4% | 419.0% | 263.8% | 427.2% | 341.5% |
Avg | -77.0% | 113.8% | 39.2% | 87.0% | 61.3% |
Low | - | - | -92.5% | -95.9% | -58.4% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.18 | 2.16 | -0.26 | 1.85 | 4.87 |
Avg | -2.77 | -2.28 | -2.30 | -1.69 | 0.78 |
Low | -3.35 | -3.72 | -3.89 | -3.94 | -2.39 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.